Cryoport, Inc. (CYRX) stock

CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3025% above fair value

$19.89−0.21 (-1.04%)

Close on Nov 13, 2026Market cap $1.01BP/E –Yield –

Cryoport EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cryoport's EV/EBITDA was 203.3× on Apr 29, 2022.

Period	Period end	Value	Change (pts)
2022	Apr 29, 2022	203.3×	−592.8
2021	Dec 31, 2021	796.1×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CYRX.

Revenue growth11.8% · median 1.0%

Gross margin46.9% · median 45.7%

Operating margin-20.0% · median -5.7%

Net margin-21.5% · median 2.9%

Advertisement
300 × 250

See a number that looks wrong?